Polynovo (ASX:PNV) share price rises despite widening losses

The Polynovo Ltd (ASX:PNV) share price is rising slightly today, despite the company reporting a loss for the first half of FY2021.

| More on:
A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Polynovo Ltd (ASX: PNV) shares are swinging around today after the company released its earnings report for the first half of the 2021 financial year (1H21) before market open this morning. At the time of writing, the Polynovo share price has risen 0.83% to $2.43 after climbing as high as $2.47 earlier in the day.

What did Polynovo report this morning?

Polynovo is an ASX health care company that specialises in treatments for burn injuries and other skin maladies.

The Polynovo share price is staying afloat today after the biotech reported that revenues for 1H21 came in at $12.8 million, up 25.3% over the $10.2 million from the prior corresponding period (1H20). Gross margins for product sales rose 3.9% as well.

However, that was offset by expenses increasing 32.6% from $11.2 million in 1H20 to $13 million in 1H21. A large component of this increase came from increased staff headcount.

That rise in expenses helped push earnings before interest, tax, depreciation and amortisation (EBITDA) to a loss of $2.9 million, up 46.2% from the previous loss of $1 million. Earnings before interest and tax (EBIT) losses also rose 41%, going from a loss of $2.4 million in 1H20 to a loss of $3.3 million in 1H21.

That resulted in Polynovo delivering a net profit after tax loss of $3.54 million, up 46.3% from the $2.42 million loss of 1H20.

Overall, the company posted an underlying loss of $0.87 million for 1H21, down 40.2% from its loss of $1.45 million in 1H20. No dividend was announced, in case you were wondering.

Polynovo has blamed the coronavirus pandemic on "lumpy" revenues for the period, citing "reduced access and reduced elective surgery in all regions".

Even so, the company has pointed to a 31.2% rise in sales of its flagship NovoSorb product as a bright spot over the period. It also highlighted the fact it managed to sign 22 additional customers in the United States, which brings the total new accounts opened for the 2020 calendar year to 109. That's an 89% rise over the 2019 calendar year.

About the Polynovo share price

Although the Polynovo share price is having a decent day today, the company has had a rough start to the year. Polynovo shares remain down 37.15% year to date, and down more than 14% over the past 12 months. In saying that, Polynovo shares are still up more than 1,170% since August 2017.

On the current Poynovo share price, the company has a market capitalisation of around $1.61 billion.

Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A young well-dressed couple at a luxury resort celebrate successful life choices.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors kept up the selling this session.

Read more »

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Broker Notes

Morgans says these ASX 200 shares can rise 20%+

The broker says these shares could offer major upside.

Read more »

Three women athletes lie flat on a running track as though they have had a long hard race where they have fought hard but lost the event.
Broker Notes

Brokers rate 2 ASX All Ords rippers of 2025: Is their phenomenal run over?

Both of these ASX shares more than tripled in value last year.

Read more »

a woman puts her hand to her chin and looks to the side deep in thought as though pondering something significant.
Broker Notes

2 ASX 200 gold shares to buy and 1 to sell: experts

After exceptional share price growth for 2 years, experts say investors need to choose their gold stocks carefully.

Read more »

Bored man sitting at his desk with his laptop.
Share Fallers

Why 4DMedical, ARB, Inghams, and Qoria shares are tumbling today

These shares are under pressure on Tuesday. What's going on?

Read more »

Two smiling work colleagues discuss an investment at their office.
Share Market News

Why Bellevue Gold, DroneShield, Hub24, and Telix shares are storming higher today

These shares are rising on Tuesday despite the market weakness.

Read more »

Keyboard button with the word sell on it, symbolising the time being right to sell ASX stocks.
Resources Shares

ASX 200 materials was the best sector of 2025 but it's time to sell these 3 shares: broker

Morgan Stanley has just updated its ratings and 12-month price targets on 3 ASX 200 mining shares.

Read more »

A red heart-shaped balloon float up above the plain white ones, indicating the best shares
Dividend Investing

Why this could be the best ASX dividend stock to buy today

There are few ideas that match this option for dividend investors.

Read more »